...
首页> 外文期刊>OncoTargets and therapy >Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review
【24h】

Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review

机译:恶性心包积液对晚期肺癌患者心包内贝伐单抗的持续反应:一例病例并文献复习

获取原文
           

摘要

Abstract: Malignant pericardial effusion (MPCE) is a common complication of advanced malignant tumors, and interferes severely with patient prognosis and quality of life. The standard treatment for this complication is intracavitary perfusion of chemotherapeutic drugs, which is limited by unsatisfactory therapeutic effects and serious adverse events. We report a patient with MPCE who was treated with bevacizumab by pericardial perfusion, resulting in a complete response. This case supports the use of intrapericardial bevacizumab as a potential treatment for MPCE.
机译:摘要:恶性心包积液(MPCE)是晚期恶性肿瘤的常见并发症,严重干扰患者的预后和生活质量。这种并发症的标准治疗方法是腔内灌注化疗药物,其治疗效果欠佳和严重的不良事件受到限制。我们报告了通过心包灌注用贝伐单抗治疗的MPCE患者,获得了完全缓解。该病例支持使用心包内贝伐单抗作为MPCE的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号